Opinion|Videos|April 1, 2026
Addressing Safety Concerns and Mitigating Toxicities in EGFR-Mutated NSCLC
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss safety and toxicity management in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, explore proactive and reactive strategies to manage adverse effects associated with frontline EGFR-directed regimens in non–small cell lung cancer. Spira discusses prophylaxis measures and monitoring approaches to mitigate infusion-related reactions, dermatologic toxicities, and other class-specific effects. Raez outlines dose modification strategies and supportive care interventions aimed at maintaining treatment intensity while preserving quality of life.
Advertisement
Related to this article
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
5